Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3012% below fair value
$20.94−1.89 (-8.28%)
Close on Nov 16, 2026Market cap $2.16BP/E –Yield –
Beam Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Beam Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$359.38M. For fiscal 2025 it was -$345.10M. The highest annual figure on record is $22.53M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$345.10M | – |
| FY2024 | Dec 31, 2024 | -$347.25M | – |
| FY2023 | Dec 31, 2023 | -$149.20M | -762.3% |
| FY2022 | Dec 31, 2022 | $22.53M | – |
| FY2021 | Dec 31, 2021 | -$66.27M | – |
| FY2020 | Dec 31, 2020 | -$95.74M | – |
| FY2019 | Dec 31, 2019 | -$72.00M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$66.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$128.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$83.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$81.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$76.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$103.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$76.37M | -156.5% |
| Q3 FY2024 | Sep 30, 2024 | -$88.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$83.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$99.75M | – |
| Q4 FY2023 | Dec 31, 2023 | $135.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$89.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$84.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$109.82M | -150.3% |
| Q4 FY2022 | Dec 31, 2022 | -$69.19M | -3880.9% |
| Q3 FY2022 | Sep 30, 2022 | -$74.50M | -2577.4% |
| Q2 FY2022 | Jun 30, 2022 | -$52.28M | – |
| Q1 FY2022 | Mar 31, 2022 | $218.49M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.83M | – |
| Q3 FY2021 | Sep 30, 2021 | $3.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$32.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$38.58M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.21M | – |
| Q2 FY2020 | Jun 30, 2020 | -$22.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.39M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.86M | – |
See a number that looks wrong?